About Crossject

A fast-growing
Specialty Pharma

Une patiente s’injecte ZENEO® dans la cuisse

CROSSJECT is a Specialty Pharma company developing innovative solutions for emergency situations, based on its unique needle-free auto-injector technology, ZENEO®.

The Company is notably at an advanced stage of regulatory development for ZEPIZURE®, an emergency treatment for severe epileptic seizures, which is the subject of, among others, a contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA)*.

*BARDA Contract Number: 75A50122C00031. This contract was signed with BARDA, which operates under the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS).

Discover ZEPIZURE®

The versatile ZENEO® platform is designed to enable untrained patients or caregivers to easily and instantly administer a wide range of emergency medications via intramuscular injection, either on bare skin or through clothing. The company is also developing additional products focused on treating allergic shocks, adrenal insufficiency, and other emergency medicine indications, as well as therapies for other critical conditions.

Who are we?

Who we are: ZENEO®, a unique technology platform to save lives simply, adaptable to dozens of molecules, with an ergonomic design for emergencies. Our activities: develop, manufacture, sell. Finance: a company listed on Euronext Growth Paris. An international team: more than 100 employees in France and the USA.

Three priority
emergency products

Three targeted products (epileptic seizures, acute adrenal insufficiency crisis, allergic shock) addressing unmet medical needs where patients’ lives are at stake.

Discover our pipeline

Presence
in North America

Strengthening presence for commercialization in the USA, starting with ZEPIZURE®.

Contract with BARDA*

In 2022, BARDA placed a firm order worth $60 million with CROSSJECT for an initial delivery to the U.S. Strategic National Stockpile, contingent upon FDA authorization.

BARDA also funds the continued development and regulatory activities for ZEPIZURE® in the United States until FDA approval is obtained. Additionally, BARDA holds an option to purchase additional auto-injectors from CROSSJECT. The total value of the contract, if all options are exercised, would amount to $155 million.